TRAJENTA®

Linagliptin

Patient Profiles

How can TRAJENTA® help your adult patients with type 2 diabetes?

The following are fictitious characters and hypothetical scenarios.

TONY: T2D patient with hypoglycaemic episodes

T2D for 10 years
Blood pressure and lipid profile at target
Reduced kidney function
No history of CV disease
Mild non-proliferative diabetic retinopathy
Patient stopped glimepiride 2 mg bd recently (of his own accord) after frequent palpitations and sweating

HbA1c 7.5% (58.5 mmol/mol)
Fasting blood glucose 8.4 mmol/l
Blood pressure 130/75 mmHg
eGFR 56 ml/min/1.73 m²
UACR 3 mg/mmol (26.55 mg/g)
LDL-C 1.3 mmol/l

Metformin 1000 mg bd | Empagliflozin 25 mg od
Ramipril 5 mg od
Simvastatin 40 mg od

CAROL: Polypharmacy T2D patient

T2D since 2013
Hypertension
Hypercholesterolemia
Insomnia
Shoulder pain
Reduced kidney function

BMI 27.6 kg/m²
BP 141/88 mmHg
Fasting blood glucose 9.5 mmol/l
HbA1c 8.4% (68 mmol/mol)
Total cholesterol 5.6 mmol/l
eGFR 52 mL/min/1.73m²

Since hurting her shoulder, Carol has a sedentary lifestyle as she is not able to play tennis
She feels overwhelmed by her treatment and does not always take her medication as she should
HbA1c levels has been increasing during the last year from 7.3% to 8.4%
eGFR levels show that she has moderate renal impairment (CKD3a)

Metformin 1,000 mg bd
Atorvastatin 20 mg od
Lisinopril 10 mg od
Hydrochlorothiazide 12.5 mg od
Paracetamol as needed for pain

JOHN: Frail and elderly with high risk of hypos

T2D since 2010
Hypertension
Hypothyroid
Insomnia
Mild dementia
Atrial fibrillation

BMI 27 kg/m²
BP 120/76 mmHg
Fasting blood glucose 8.4 mmol/l
HbA1c 9.5% (80 mmol/mol)
Total cholesterol 5.0 mmol/l
eGFR 66 mL/min/1.73 m²

John has had episodes of daytime drowsiness and confusion
He is becoming increasingly frail and dependent with his activities of daily living. He continues to live in sheltered housing but can only walk short distances now with a stick
He has recently been admitted to hospital following a major hypoglycaemic event
His admission thyroid function tests (TFTs) were normal

Metformin 500 mg bd
Gliclazide modified release 30 mg bd
Atorvastatin 20 mg
Ramipril 10 mg od
Warfarin variable dose
Levothyroxine 75 mcg od
Zolpidem 5 mg od

What benefits could TRAJENTA® offer a patient like John?

TRAJENTA® has a low incidence of hypoglycaemia vs placebo¹
Looking at his current treatment, it would be best to stop gliclazide (a sulphonylurea) because of the increased risk of hypoglycaemia⁶
TRAJENTA® is an ideal option for John who, owing to the nature of a recent major hypoglycaemic event, should not be exposed to risk of further hypoglycaemic events¹
Increasing age, frailty and renal disease in patients with type 2 diabetes are risk factors for hypoglycaemia⁷

Footnote

*BD: Twice daily; BMI: Body mass index; BP: Blood pressure; CKD: Chronic kidney disease; GFR: estimated glomerular filtration rate; OD: Once daily; T2D: Type 2 diabetes; TFTs: Thyroid function tests; UACR: Urinary albumin-to-creatinine ratio.

References

1.

TRAJENTA® (linagliptin) Summary of Product Characteristics. SmPCs available at EMC: www.medicines.org.uk (GB) and https://www.emcmedicines.com/en-GB/northernireland/ (NI)

2.

Sitagliptin Summary of Product Characteristics. SmPCs available at EMC: www.medicines.org.uk (GB) and www.emcmedicines.com/en-GB/northernireland/ (NI).

3.

Vildagliptin Summary of Product Characteristics. SmPC available at EMC: www.medicines.org.uk (GB).

4.

Saxagliptin Summary of Product Characteristics. SmPCs available at EMC: www.medicines.org.uk (GB) and www.emcmedicines.com/en-GB/northernireland/ (NI).

5.

Alogliptin Summary of Product Characteristics. SmPCs available at EMC: www.medicines.org.uk (GB) and www.emcmedicines.com/en-GB/northernireland/ (NI).

6.

Davies M et al. Diabetologia 2018; 61 (12): 2461–2498.

7.

Abdelhafiz AH, et al. Aging Dis. 2015;6(2):156-167.

PC-GB-105693 V2

December 2022